Maxcyte, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 9, 2023 and accepted by EDGAR at Aug 9, 2023, 20:55 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $5.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $10.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $1.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $2.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | $7.7m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-01-01 to 2023-06-30 | $15.2m | us-gaap:GrossProfit |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $5.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $11.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$13.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$26.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$10.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$21.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | −$0.10 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$0.10 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 103,063,606 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 102,955,422 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$14.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $2.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $54.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $236.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $271.2m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $13.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $30.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-06-30 | $241.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-23-014306. Last ingested by Listed: Oct 24, 2026, 15:10 ET. Listed shows no prices and gives no investment advice.